（记者 曾健辉） 截至发稿，创新医疗市值为93亿元。 每经头条（nbdtoutiao）——专访管涛：美国政府经济贸易政策正逐渐动摇美元本位国际货币体系，利 多因素下人民币汇率有可能破7 每经AI快讯，创新医疗（SZ 002173，收盘价：20.98元）12月12日晚间发布公告称，公司第七届2025年 第四次董事会临时会议于2025年12月11日以通讯表决方式召开。会议审议了《关于同意签署参股公司全 诊医学〈B+轮增资协议〉〈B+轮股东协议〉及相关文件的议案》等文件。 2025年1至6月份，创新医疗的营业收入构成为：医疗服务业务占比99.73%，其他业务占比0.27%。 ...

证券代码：002173 证券简称：创新医疗 公告编号：2025-056 创新医疗管理股份有限公司 关于签署参股公司全诊医学《B+轮增资协议》 《B+轮股东协议》及相关文件的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本次交易概述 （一）交易基本情况 创新医疗管理股份有限公司（以下简称"公司"）于 2024 年 8 月 28 日召开 的第六届董事会 2024 年第六次临时会议，审议通过了《关于投资杭州全诊医学 科技有限公司的议案》，同意公司对杭州全诊医学科技有限公司（以下简称"全 诊医学"）进行战略投资，具体内容详见公司 2024 年 8 月 29 日、2024 年 11 月 1 日发布于巨潮资讯网（http://www.cninfo.com.cn）的相关公告。 公司于 2025 年 6 月 30 日召开了第六届董事会 2025 年第五次临时会议，审 议通过了《关于同意签署参股公司全诊医学〈B 轮增资及转股协议〉〈B 轮股东 协议〉及相关文件的议案》，同意公司签署《杭州全诊医学科技有限公司 B 轮增 资及转股协议》《杭州全诊医学科技有限公司 B 轮 ...

证券代码：002173 证券简称：创新医疗 公告编号：2025-055 创新医疗管理股份有限公司 第七届董事会 2025 年第四次临时会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 创新医疗管理股份有限公司（以下简称"公司"）第七届董事会于 2025 年 12 月 11 日召开了 2025 年第四次临时会议。本次会议以通讯表决方式召开。会 议通知于 2025 年 12 月 9 日以书面形式发出。本次会议由陈海军董事长主持，应 出席董事 9 名，实际出席 9 名。本次会议召开符合《公司法》及公司《章程》的 规定，合法有效。 二、董事会会议审议情况 与会董事就议案进行了审议、表决，以 9 票赞成、0 票反对、0 票弃权的表 决结果一致通过了《关于同意签署参股公司全诊医学〈B+轮增资协议〉〈B+轮股 东协议〉及相关文件的议案》。 同意公司签署《杭州全诊医学科技有限公司 B+轮增资协议》、《杭州全诊医 学科技有限公司 B+轮股东协议》以及杭州全诊医学科技有限公司（以下简称"全 诊医学"）本轮增资所涉股东会决议等相关文件，同意公司放 ...

创新医疗公告称，公司第七届董事会2025年第四次临时会议以通讯表决方式召开，9名董事全部出席。 会议以9票赞成、0票反对、0票弃权，一致通过《关于同意签署参股公司全诊医学〈B+轮增资协议〉 〈B+轮股东协议〉及相关文件的议案》，同意签署全诊医学B+轮增资等相关文件，并放弃本次融资中 的优先认购权或其他类似权利。 ...

Core Insights - Mirxes has been awarded the "Sunshine" Award for its innovative non-invasive early screening technology, GASTROClear™, which has been recognized for its significant clinical value in the field of gastric cancer early detection [1][3]. Group 1: Award and Recognition - The "Sunshine" Award is part of the 21st Century Health Industry Competitiveness Research, which aims to promote high-quality development in the health industry and support the "Healthy China" strategy [3]. - GASTROClear™ is the first non-invasive gastric cancer screening product in China to receive NMPA Class III medical device registration, marking a significant advancement in the field [4][5]. Group 2: Clinical and Market Impact - GASTROClear™ utilizes a proprietary miRNA technology platform to detect 12 types of microRNAs in human serum, achieving a sensitivity of 85% and a negative predictive value of 99.4%, thus effectively identifying high-risk gastric cancer patients [4]. - Gastric cancer is a major health issue in China, accounting for 43% of new global cases, with a current early diagnosis rate of less than 20% [5]. Group 3: Strategic Collaborations and Future Developments - Mirxes has entered into strategic partnerships with Watson Bio and Crystal Technology to enhance its capabilities in molecular diagnostics and AI-driven solutions for early cancer detection and intervention [6][7]. - The company aims to build an integrated ecosystem from diagnosis to treatment, leveraging its technological innovations and strategic collaborations to expand its market presence globally [7].

Group 1: Industrial Mother Machine Sector - The industrial mother machine sector shows a positive trend with a total index increase of 1.29% to 1754.21 [2] - Key stocks in this sector include: - GuoJi Heavy Industry (601399) with a price of 4.63, up by 9.98% and 42.46% over the past five days [2] - China First Heavy Industries (601106) at 3.42, also up by 9.97% and 13.62% over the last five days [2] - Weihong Co., Ltd. (300508) at 38.12, increasing by 9.29% and 10.05% in five days [2] - Other notable performers include: - Yuhuan CNC (002903) at 24.54, up by 6.70% [2] - Ruineng Technology (603933) at 30.40, with a 5.89% increase [2] Group 2: Brain-Computer Interface Sector - The brain-computer interface sector experienced significant activity, highlighted by the upcoming "Brain Link World, Intelligence Gathering in Shanghai" conference scheduled for December 4-5, 2025 [3] - Key stocks in this sector include: - Dineike (300884) with a price of 16.82, up by 14.34% and 18.09% over the past five days [3] - Nanjing Panda (600775) at 12.55, increasing by 9.99% and 13.78% [3] - Chengyitong (300430) at 18.99, up by 3.94% [3] - Other stocks showing positive movement include: - Beiyikang (920199) at 34.70, up by 3.89% [3] - Innovation Medical (002173) at 22.29, with a 3.05% increase [3]

证券之星消息，截至2025年12月4日收盘，创新医疗(002173)报收于21.63元，下跌4.76%，换手率 7.39%，成交量30.75万手，成交额6.72亿元。 12月4日的资金流向数据方面，主力资金净流出5637.55万元，占总成交额8.39%，游资资金净流出 2262.9万元，占总成交额3.37%，散户资金净流入7900.45万元，占总成交额11.75%。 近5日融资融券数据一览见下表： 创新医疗融资融券信息显示，融资方面，当日融资买入3346.52万元，融资偿还3878.66万元，融资净偿 还532.14万元。融券方面，融券卖出0.0股，融券偿还0.0股，融券余量0.0股，融券余额0.0万元。融资融 券余额3.8亿元。 该股主要指标及行业内排名如下： | 指标 | 创新医疗 | 医疗服务行业均值 | 行业排名 | | --- | --- | --- | --- | | 总市值 | 95.45 乙元 | 181.25亿元 | 14 43 | | 净资产 | 17.9亿元 | 58.61亿元 | 27 43 | | 净利润 | 472.44万元 | 4.59亿元 | 34 43 | | 市盈率(动) ...

Group 1 - The high-pressure oxygen chamber concept increased by 0.92%, ranking second among concept sectors, with eight stocks rising, including Hangzhou Oxygen, Dahu Co., and Jinling Pharmaceutical, which rose by 5.56%, 1.13%, and 1.09% respectively [1] - The leading stocks in terms of net inflow of main funds in the high-pressure oxygen chamber sector include Samsung Medical, with a net inflow of 4.9759 million yuan, followed by Aoyang Health, Yingkang Life, and Weiao Co. [2][3] - The net inflow ratios for Yingkang Life, Weiao Co., and Aoyang Health were 2.53%, 1.60%, and 1.49% respectively, indicating strong interest from main funds [3] Group 2 - The high-pressure oxygen chamber sector experienced a net outflow of 45 million yuan today, despite some stocks seeing net inflows [2] - Stocks with significant declines include Beiyikang, China Railway Construction, and Yingkang Life, which fell by 0.40%, 0.20%, and 0.20% respectively [1] - The trading volume and turnover rates for stocks like Hangzhou Oxygen and International Medical showed negative net inflows, indicating potential selling pressure [4]

证券之星消息，截至2025年12月2日收盘，创新医疗(002173)报收于22.54元，上涨2.18%，换手率 9.64%，成交量40.13万手，成交额9.0亿元。 12月2日的资金流向数据方面，主力资金净流入6300.77万元，占总成交额7.0%，游资资金净流出1961.3 万元，占总成交额2.18%，散户资金净流出4339.48万元，占总成交额4.82%。 近5日资金流向一览见下表： 创新医疗融资融券信息显示，融资方面，当日融资买入6878.25万元，融资偿还5160.85万元，融资净买 入1717.4万元，连续3日净买入累计3790.77万元。融券方面，融券卖出0.0股，融券偿还0.0股，融券余量 0.0股，融券余额0.0万元。融资融券余额3.82亿元。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 近5日融资融券数据一览见下表： 该股主要指标及行业内排名如下： | | | | 指标 | 创新医疗 | 医疗服务行业均值 | 行业排名 | | --- | --- | --- | --- | | 总市值 | 99.47亿元 | ...

Core Points - Shandong Province has introduced two new policies to streamline the approval process for innovative medical devices, effective from January 1, 2026, aimed at overcoming market entry barriers and promoting high-quality industry development [1][2] - The new policies establish clear criteria for innovative medical devices, requiring products to be domestically original in mechanism, significantly improve performance and safety compared to similar products, and have completed standardized preliminary research [1] - Approved innovative products will enter a "fast track" with technical review and administrative approval timelines reduced to 20 and 5 working days, respectively, significantly faster than conventional processes [1][2] Summary by Sections Innovative Medical Device Approval - The new regulations specify that applicants must hold patent rights or usage rights to core technologies [1] - A public announcement period of no less than 10 working days will be implemented to ensure transparency in the approval process [1] Priority Approval for Clinically Urgent Devices - The priority approval process includes devices for rare diseases, cancer treatment, and specialized medical devices for the elderly and children [2] - Eligible products will benefit from a "three-priority" service, with inspection, technical review, and administrative approval timelines set at 50, 30, and 5 working days, respectively [2] Regulatory Mechanisms - A comprehensive regulatory mechanism will be established to maintain safety standards throughout the approval process [2] - The policies adhere to principles of early intervention, tailored strategies, collaborative review, and full guidance, with a clear exit mechanism for non-compliant applicants [2] - If an innovative medical device is not registered within five years of approval, it will automatically lose its innovative status, aligning with the regulatory goal of "combining regulation and management" [2]